ReviewGeneral thoracic and cardiovascular surgery2026
Minimally invasive cardiac surgeries in 2023-annual report of the Japanese association for minimally invasive cardiac surgery.
Review in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling the Chasm in Japanese robot-assisted surgery diffusion: the interplay of surgical volume and intra-specialty spillover.Journal of robotic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo establish updated nationwide perioperative benchmarks for minimally invasive cardiac surgery (MICS) in Japan by presenting the 2023 annual report and summarizing procedural trends from 2021 to 2023.
methodsData on mitral valve (MV) surgery, aortic valve replacement (AVR), coronary artery bypass grafting (CABG), atrial septal defect (ASD) closure, and cardiac tumor resection performed via MICS in 2023 were extracted from the Japan Cardiovascular Surgery Database. Perioperative outcomes, including 30-day mortality, in-hospital mortality, conversion to median sternotomy, and major morbidity, were evaluated. Three-year trends in case volume, institutional distribution, procedural complexity, and early outcomes were descriptively reviewed.
resultsThe 2023 MICS cohort included the following cases: MV surgery (n = 3367), AVR (n = 1352), isolated CABG (n = 564), ASD closure (n = 232), and cardiac tumor resection (n = 126). Thirty-day and in-hospital mortality rates were 0.2% and 0.2%, respectively, in isolated MV repair, 1.3% and 1.9% in isolated MV replacement, 0.1% and 0.3% in isolated AVR, 0.9% and 1.2% in isolated CABG, 0% and 0% in ASD closure, and 0.8% and 1.6% in cardiac tumor resection. Among isolated procedures, the incidence of conversion to median sternotomy ranged from 0% to 2.6%. Over 2021-2023, case volume increased in all major categories, particularly in MV surgery and AVR, whereas MICS-CABG showed increasing complexity while maintaining acceptable early outcomes.
conclusionsNationwide MICS activity in Japan has expanded progressively over the past 3 years in both volume and procedural scope, while generally favorable early outcomes have been maintained. These updated results provide an important benchmark for ongoing quality assessment in contemporary MICS practice.
Indexed as
Identifiers
42690581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.